<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455908</url>
  </required_header>
  <id_info>
    <org_study_id>IL-2 off label</org_study_id>
    <nct_id>NCT02455908</nct_id>
  </id_info>
  <brief_title>IL-2 for Multi Drug Resistant Nephrotic Syndrome</brief_title>
  <official_title>Use of IL-2 for Pediatric, Multi Drug Resistant, Idiopathic Nephrotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Giannina Gaslini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Giannina Gaslini</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to design an open-label phase 1-2 trial to assess safety and clinical
      and immunologic effects of repeated administration of recombinant low dose IL2 (Proleukin) in
      5 patients with idiopathic nephrotic syndrome unresponsive to drugs (steroids, calcineurin
      inhibitors, Rituximab), following the therapeutical scheme indicated for crioglobulinemic
      nephropathy:

      cycle1: IL2 1x106 /m2 s.c for 5 consecutive days cycle2: IL2 1.5 x106 / m2 s.c for 5
      consecutive days, starting from 3 weeks after the first cycle.

      cycle3: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 6 weeks after the first
      cycle.

      Cycle 4: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 9 weeks after the first
      cycle.

      Current therapy with steroids and calcineurin inhibitors (Prograf) will be maintained during
      the first cycle and progressively reduced during the subsequent cycles.

      The first cycle will be performed during hospitalization in the investigators Unit;
      subsequent cycles will be performed at nephrology outpatients. All laboratory values normally
      utilized in the follow up of patients affected by idiopathic nephrotic syndrome will be
      evaluated during the first week of treatment and at the end of the protocol, together with
      specific cellular values (Tregs, B cells, NK).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>Change from baseline at 30, 60 and 180 days after first cycle (5 days)</time_frame>
    <description>Complete remission is defined by urinary protein/creatinine ratio (uPCR) &lt;200 mg/g (&lt;20mg/mmol) for 3 consecutive days. Partial remission is defined as proteinuria reduction of 50% or greater from the presenting value and absolute uPCR between 200 and 2000 mg/g. for 3 consecutive days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tregs Levels</measure>
    <time_frame>Immediately before first cycle and 30, 60 and 180 days after first cycle (5 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>Change from baseline at 30, 60 and 180 days after first cycle (5 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>From day 1 to day 5 of each cycle. The study includes 5 cycles, each one lasting 5 days.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Proleukin®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous administration of low doses of IL2 (Proleukin) following the therapeutical scheme indicated for crioglobulinemic nephropathy:
cycle1: IL2 1x106 /m2 s.c for 5 consecutive days cycle2: IL2 1.5 x106 / m2 s.c for 5 consecutive days, starting from 3 weeks after the first cycle.
cycle3: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 6 weeks after the first cycle.
Cycle 4: IL2 1.5 x106 /m2 s.c for 5 consecutive days, starting from 9 weeks after the first cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proleukin®</intervention_name>
    <arm_group_label>Proleukin®</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Drug resistance: persistence of proteinuria in nephrotic range after a cycle of
             steroids of at least 3 months and an association with cyclosporine/tacrolimus for at
             least other 6 months

          -  Parents'/guardian's written informed consent, and child's assent given before any
             study-related procedure not part of the subject's normal medical care, with the
             understanding that consent may be withdrawn by the subject at any time without
             prejudice to his or her future medical care.

          -  Age between 2 and 18 years

          -  Histological pattern of minimal change disease, mesangial proliferation with IgM
             deposits or focal segmental glomerulosclerosis

        Exclusion Criteria:

          -  Positivity to autoimmunity tests (ANA, dsDNA, ANCA).

          -  Reduction of C3 levels.

          -  Hystological pattern characterized by elements suggestive for congenital disease:
             diffuse mesangial sclerosis without IgM deposits, cystic-like tubular dilatation,
             mitochondrial abnormalities evident on electron microscopy, IF suggestive for
             congenital collagen 4 disease.

          -  Histological pattern not suitable with INS in the pediatric age (membranous
             glomerulonephritis, lupus nephritis, diffuse and/or localized vasculitis, amyloidosis)

          -  Homozygous or heterozygous mutations of to the 3 genes (NPHS1, NPHS2, WT1) whose
             mutations are known to be responsible of almost 80% of familiar cases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gian Marco Ghiggeri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Giannina Gaslini</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Trompeter RS, Lloyd BW, Hicks J, White RH, Cameron JS. Long-term outcome for children with minimal-change nephrotic syndrome. Lancet. 1985 Feb 16;1(8425):368-70.</citation>
    <PMID>2857421</PMID>
  </reference>
  <reference>
    <citation>Sanna-Cherchi S, Caridi G, Weng PL, Scolari F, Perfumo F, Gharavi AG, Ghiggeri GM. Genetic approaches to human renal agenesis/hypoplasia and dysplasia. Pediatr Nephrol. 2007 Oct;22(10):1675-84. Epub 2007 Apr 17. Review. Erratum in: Pediatr Nephrol. 2007 Oct;22(10):1685-6.</citation>
    <PMID>17437132</PMID>
  </reference>
  <reference>
    <citation>Pollak MR. Familial FSGS. Adv Chronic Kidney Dis. 2014 Sep;21(5):422-5. doi: 10.1053/j.ackd.2014.06.001. Review.</citation>
    <PMID>25168831</PMID>
  </reference>
  <reference>
    <citation>Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant. 2005 Jun;5(6):1179-85. Review.</citation>
    <PMID>15888021</PMID>
  </reference>
  <reference>
    <citation>Reiser J, von Gersdorff G, Loos M, Oh J, Asanuma K, Giardino L, Rastaldi MP, Calvaresi N, Watanabe H, Schwarz K, Faul C, Kretzler M, Davidson A, Sugimoto H, Kalluri R, Sharpe AH, Kreidberg JA, Mundel P. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004 May;113(10):1390-7.</citation>
    <PMID>15146236</PMID>
  </reference>
  <reference>
    <citation>Bertelli R, Bodria M, Nobile M, Alloisio S, Barbieri R, Montobbio G, Patrone P, Ghiggeri GM. Regulation of innate immunity by the nucleotide pathway in children with idiopathic nephrotic syndrome. Clin Exp Immunol. 2011 Oct;166(1):55-63. doi: 10.1111/j.1365-2249.2011.04441.x. Epub 2011 Jul 15.</citation>
    <PMID>21762125</PMID>
  </reference>
  <reference>
    <citation>Ghiggeri GM, Cercignani G, Ginevri F, Bertelli R, Zetta L, Greco F, Candiano G, Trivelli A, Gusmano R. Puromycin aminonucleoside metabolism by glomeruli and glomerular epithelial cells in vitro. Kidney Int. 1991 Jul;40(1):35-42.</citation>
    <PMID>1921153</PMID>
  </reference>
  <reference>
    <citation>Ginevri F, Gusmano R, Oleggini R, Acerbo S, Bertelli R, Perfumo F, Cercignani G, Allegrini S, D'Allegri F, Ghiggeri G. Renal purine efflux and xanthine oxidase activity during experimental nephrosis in rats: difference between puromycin aminonucleoside and adriamycin nephrosis. Clin Sci (Lond). 1990 Mar;78(3):283-93.</citation>
    <PMID>2156648</PMID>
  </reference>
  <reference>
    <citation>Garin EH, Diaz LN, Mu W, Wasserfall C, Araya C, Segal M, Johnson RJ. Urinary CD80 excretion increases in idiopathic minimal-change disease. J Am Soc Nephrol. 2009 Feb;20(2):260-6. doi: 10.1681/ASN.2007080836. Epub 2008 Dec 3.</citation>
    <PMID>19056875</PMID>
  </reference>
  <reference>
    <citation>Le Berre L, Bruneau S, Naulet J, Renaudin K, Buzelin F, Usal C, Smit H, Condamine T, Soulillou JP, Dantal J. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol. 2009 Jan;20(1):57-67. doi: 10.1681/ASN.2007111244. Epub 2008 Nov 19.</citation>
    <PMID>19020006</PMID>
  </reference>
  <reference>
    <citation>Wang YM, Zhang GY, Hu M, Polhill T, Sawyer A, Zhou JJ, Saito M, Watson D, Wu H, Wang Y, Wang XM, Wang Y, Harris DC, Alexander SI. CD8+ regulatory T cells induced by T cell vaccination protect against autoimmune nephritis. J Am Soc Nephrol. 2012 Jun;23(6):1058-67. doi: 10.1681/ASN.2011090914. Epub 2012 Apr 5.</citation>
    <PMID>22491420</PMID>
  </reference>
  <reference>
    <citation>Bertelli R, Di Donato A, Cioni M, Grassi F, Ikehata M, Bonanni A, Rastaldi MP, Ghiggeri GM. LPS nephropathy in mice is ameliorated by IL-2 independently of regulatory T cells activity. PLoS One. 2014 Oct 24;9(10):e111285. doi: 10.1371/journal.pone.0111285. eCollection 2014.</citation>
    <PMID>25343479</PMID>
  </reference>
  <reference>
    <citation>Polhill T, Zhang GY, Hu M, Sawyer A, Zhou JJ, Saito M, Webster KE, Wang Y, Wang Y, Grey ST, Sprent J, Harris DC, Alexander SI, Wang YM. IL-2/IL-2Ab complexes induce regulatory T cell expansion and protect against proteinuric CKD. J Am Soc Nephrol. 2012 Aug;23(8):1303-8. doi: 10.1681/ASN.2011111130. Epub 2012 Jun 7.</citation>
    <PMID>22677553</PMID>
  </reference>
  <reference>
    <citation>Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, Sene D, Cacoub P, Klatzmann D. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011 Dec 1;365(22):2067-77. doi: 10.1056/NEJMoa1105143. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.</citation>
    <PMID>22129253</PMID>
  </reference>
  <reference>
    <citation>Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 1;365(22):2055-66. doi: 10.1056/NEJMoa1108188.</citation>
    <PMID>22129252</PMID>
  </reference>
  <reference>
    <citation>Bertelli R, Trivelli A, Magnasco A, Cioni M, Bodria M, Carrea A, Montobbio G, Barbano G, Ghiggeri GM. Failure of regulation results in an amplified oxidation burst by neutrophils in children with primary nephrotic syndrome. Clin Exp Immunol. 2010 Jul 1;161(1):151-8. doi: 10.1111/j.1365-2249.2010.04160.x. Epub 2010 May 19.</citation>
    <PMID>20491793</PMID>
  </reference>
  <reference>
    <citation>Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science. 2006 Mar 31;311(5769):1924-7. Epub 2006 Feb 16.</citation>
    <PMID>16484453</PMID>
  </reference>
  <reference>
    <citation>Kim MG, Koo TY, Yan JJ, Lee E, Han KH, Jeong JC, Ro H, Kim BS, Jo SK, Oh KH, Surh CD, Ahn C, Yang J. IL-2/anti-IL-2 complex attenuates renal ischemia-reperfusion injury through expansion of regulatory T cells. J Am Soc Nephrol. 2013 Oct;24(10):1529-36. doi: 10.1681/ASN.2012080784. Epub 2013 Jul 5.</citation>
    <PMID>23833258</PMID>
  </reference>
  <reference>
    <citation>Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011 Jun;6(6):1308-15. doi: 10.2215/CJN.09421010. Epub 2011 May 12.</citation>
    <PMID>21566104</PMID>
  </reference>
  <reference>
    <citation>Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int. 2013 Nov;84(5):1025-33. doi: 10.1038/ki.2013.211. Epub 2013 Jun 5.</citation>
    <PMID>23739238</PMID>
  </reference>
  <reference>
    <citation>Caridi G, Bertelli R, Di Duca M, Dagnino M, Emma F, Onetti Muda A, Scolari F, Miglietti N, Mazzucco G, Murer L, Carrea A, Massella L, Rizzoni G, Perfumo F, Ghiggeri GM. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol. 2003 May;14(5):1278-86.</citation>
    <PMID>12707396</PMID>
  </reference>
  <reference>
    <citation>Caridi G, Perfumo F, Ghiggeri GM. NPHS2 (Podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. Pediatr Res. 2005 May;57(5 Pt 2):54R-61R. Epub 2005 Apr 6. Review.</citation>
    <PMID>15817495</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Giannina Gaslini</investigator_affiliation>
    <investigator_full_name>Gian Marco Ghiggeri MD, PhD</investigator_full_name>
    <investigator_title>MD, director of Nephrology, Dialysis and Transplantation Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

